Aradigm has announced the completion of patient enrollment for ORBIT-4, a clinical trial of Pulmaquin for non-cystic fibrosis bronchiectasis.
With the Improving Access to Clinical Trials Act (IACT) of 2009 set to expire on October 5, 2015, the Cystic Fibrosis Foundation championed a new bill to make the IACT legislation permanent.
ProQR Therapeutics have begun enrolling patients in their exploratory trial for QR-010, a new therapy for cystic fibrosis.
Scientific experiments examining what happens to the faulty channel protein that causes cystic fibrosis (CF) during inflammation have yielded unexpected results.
Pulmatrix Inc will be presenting preclinical data on the pharmacokinetics and potency of PUR1900 during the upcoming 2015 North American Cystic Fibrosis Conference.
Mannitol has been found to be safe in cystic fibrosis patients and effective in improving the removal of respiratory secretions.
A team of researchers released recommendations against the use of Pseudomonas aeruginosa vaccines in patients with cystic fibrosis.
Scientists discover a small molecule that can substitute for a protein and restore a key cellular function related to the one missing in individuals with cystic fibrosis.
A study reveals that different bacterial populations in regions of the lungs of cystic fibrosis patients descend from the same bacterial strain, suggesting diverse bacteria exist in each region.
The Research Development Program of the Cystic Fibrosis Foundation has expanded its network and awarded grants to various research sites in the US.
A recent study found that P. aeruginosa status in cystic fibrosis patients can have an impact on their lung microbiota composition.
There are several therapeutic techniques for airway clearance. But with all the options, how does an RT decide which is the most effective for the patient?
A potential link may exist between metabolic fingerprints and the progression of cystic fibrosis, according to a new study.
PARI Respiratory Equipment, Inc, has announced that its proprietary Kitabis Pak has been added to the Preferred Drug List (PDL) in more states across the United States.
The movement of patients within cystic fibrosis centers appeared likely to be an important risk factor for the acquisition of shared P. aeruginosa strain infections.
New research shows that microbes contributing to cystic fibrosis are able to survive in saliva and mucus that is chemically heterogeneous.
New research from the University of Pennsylvania revealed insight into the role of thiocyanate in the development of cystic fibrosis and other inflammation linked disorders.
The FDA has approved Vertex Pharma's Orkambi, the first drug directed at treating cystic fibrosis patients 12 years and older with two copies of the F508del mutation.
Monthly administration of liposome-delivered gene therapy for cystic fibrosis (CF) improved forced expiratory volume (FEV), according to a study published in Lancet Respiratory Medicine.
Spyryx is developing inhaled peptides designed to potently degrade ENaC (epithelial sodium channels), which play a role in mucus dehydration and reduced airway clearance.